CML facts

Question 1

Nilotinib SE

Answer 1

CV
Hyperglycemia
Dyslipidemia
Hyperlipasemia
Hyperbilirubinemia
Pancreatitis
QT prolongation

Question 2

Nilotinib trial

Answer 2

ENESTnd

Question 3

Dasatinib trial

Answer 3

DASISON

Question 4

Bosutinib trial

Answer 4

BEFORE

Question 5

Dasatinib dose

Answer 5

100 mg qd

Question 6

Nilotinib dose

Answer 6

300 mg bid

Question 7

Bosuitb dose

Answer 7

400 mg qd

Question 8

Imatinib trial

Answer 8

IRIS

Question 9

Imatinib dose

Answer 9

400 mg qd

Question 10

Imatinib SE

Answer 10

Neutropenia
Fatigue
GI
Rash
Edema
Muscle cramps

Question 11

Goals of Tx

Answer 11

OS
Minimal damage to QOL
Decrease risk of long term toxicity
DMR to allow TFR

Question 12

Dasatinib SE

Answer 12

Neutropenia
Thrombocytopenia and platelet dysfunction
PHTN
Pleural effusion

Question 13

Dasatinib 2nd line trial

Answer 13

START-R

Question 14

Ponatinib 2nd/3rd line trial

Answer 14

PACE

Question 15

Ponatinib 1st line trial

Answer 15

EPIC- negative trial due to toxiicity

Question 16

Ponatinib SE

Answer 16

CV- 26%
Thrombocytopenia
Rash
Dry skin
Abdominal pain

Question 17

Ponatinib dose

Answer 17

45 mg
reduce to 15 mg if CcyR in 12 months

Question 18

Tx of AP CML

Answer 18

2nd gen are preferred with higher doses

Question 19

BP phenotype

Answer 19

50% myeloid, 33% lymphoblastic, undifferentiated and MPAL -rest

Question 20

Poor risk predictors in BP CML

Answer 20

ACA and >50% blasts
LDH
Thrombocytopenia
Prior TKI
Age > 58
Chromosome 15 aberrations

Question 21

Tx of BP CML

Answer 21

2nd gen TKI followed by allo transplant

Question 22

TFR in imatinib trial

Answer 22

STIM anD TWISTER

Question 23

TFR requirements

Answer 23

CP CML
1st line or 2nd line if intolerance
5 years of TKI (4 years for 2nd gen)
DMR> 2 years (preferred 3 years for MR4)